BRPI0406861A - Utilização de agente antimuscarìnico - Google Patents

Utilização de agente antimuscarìnico

Info

Publication number
BRPI0406861A
BRPI0406861A BR0406861-0A BRPI0406861A BRPI0406861A BR PI0406861 A BRPI0406861 A BR PI0406861A BR PI0406861 A BRPI0406861 A BR PI0406861A BR PI0406861 A BRPI0406861 A BR PI0406861A
Authority
BR
Brazil
Prior art keywords
antimuscarinic agent
present
dyspeptia
tolterodine
urgency
Prior art date
Application number
BR0406861-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Barbara H Korberly
Susan M Danehower
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32771960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0406861(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of BRPI0406861A publication Critical patent/BRPI0406861A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR0406861-0A 2003-01-22 2004-01-14 Utilização de agente antimuscarìnico BRPI0406861A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44169003P 2003-01-22 2003-01-22
PCT/IB2004/000169 WO2004064821A1 (en) 2003-01-22 2004-01-14 Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders

Publications (1)

Publication Number Publication Date
BRPI0406861A true BRPI0406861A (pt) 2006-01-03

Family

ID=32771960

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406861-0A BRPI0406861A (pt) 2003-01-22 2004-01-14 Utilização de agente antimuscarìnico

Country Status (17)

Country Link
US (2) US20060047007A1 (https=)
EP (1) EP1589958B2 (https=)
JP (1) JP2006515607A (https=)
KR (1) KR20050096147A (https=)
CN (1) CN1741796A (https=)
AT (1) ATE432070T1 (https=)
AU (1) AU2004206110A1 (https=)
BR (1) BRPI0406861A (https=)
CA (1) CA2514022C (https=)
DE (1) DE602004021233D1 (https=)
ES (1) ES2324712T5 (https=)
IL (1) IL169362A0 (https=)
MX (1) MXPA05007767A (https=)
PL (1) PL377995A1 (https=)
TW (1) TW200418447A (https=)
WO (1) WO2004064821A1 (https=)
ZA (1) ZA200505026B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030931D1 (https=) * 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
ES2322148T3 (es) * 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
NZ570492A (en) * 2006-02-13 2011-08-26 Orient Pharma Samoa Co Ltd Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
WO2011109403A1 (en) * 2010-03-01 2011-09-09 Xenoport, Inc. Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
WO1998003067A1 (en) 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
DE69942928D1 (de) 1998-08-27 2010-12-23 Pfizer Health Ab Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
HUP0203028A3 (en) * 1999-11-11 2005-07-28 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use

Also Published As

Publication number Publication date
JP2006515607A (ja) 2006-06-01
EP1589958B1 (en) 2009-05-27
KR20050096147A (ko) 2005-10-05
US20070155838A1 (en) 2007-07-05
CA2514022A1 (en) 2004-08-05
CN1741796A (zh) 2006-03-01
WO2004064821A1 (en) 2004-08-05
TW200418447A (en) 2004-10-01
CA2514022C (en) 2010-07-13
EP1589958A1 (en) 2005-11-02
ES2324712T3 (es) 2009-08-13
ATE432070T1 (de) 2009-06-15
US20060047007A1 (en) 2006-03-02
IL169362A0 (en) 2007-07-04
EP1589958B2 (en) 2012-04-11
ZA200505026B (en) 2006-07-26
MXPA05007767A (es) 2006-01-31
AU2004206110A1 (en) 2004-08-05
PL377995A1 (pl) 2006-02-20
ES2324712T5 (es) 2012-06-08
DE602004021233D1 (de) 2009-07-09

Similar Documents

Publication Publication Date Title
MXPA04003866A (es) Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
KR960703009A (ko) 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용
PY0108909A (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
SE9802073D0 (sv) New use
ATE277596T1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
EP1600167A3 (en) A pyrrolidineacetamide derivative alone in combination for treatment of CNS disorders
MXPA03006439A (es) Metodo y composiciones novedosos para tratamiento local del mal del meniere, zumbido de oidos y/o perdida de oido.
EE05315B1 (et) Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette n„htud imetajal esineva seksuaalse funktsioonih„ire ravimiseks v?i m?jutamiseks
BRPI0406861A (pt) Utilização de agente antimuscarìnico
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
NO20013414D0 (no) Ny anvendelse av melagatran
WO2003049667A3 (en) The method of treating cancer
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
WO2022026622A3 (en) Treatment of viral diseases
MXPA04001805A (es) Nueva forma de dosificacion oral de liberacion prolongada.
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
RU2002105074A (ru) Способ лечения и профилактики развития гипертрофических и келоидных рубцов
NO20042586L (no) Behandlingsfremgangsmate
MXPA02007454A (es) Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor.
MD1898G2 (ro) Remediu dermatologic stabilizat pe bază de juglonă
WO1999048483A3 (en) (-)-phenylpropanolamine as a sympathomimetic drug
RU2006146071A (ru) Средство для устранения фактора циркуляторной дисфункции
UA40384A (uk) Спосіб лікування хронічного гнійного верхньощелепного синуїту

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.